The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of
patients with cardiovascular disease. However, recurrent ischemic event occurrence during …

Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary
syndromes and/or undergoing percutaneous coronary interventions. Clopidogrel, in …

Background The relation between platelet reactivity and stent thrombosis, major bleeding,
and other adverse events after coronary artery implantation of drug-eluting stents has been …

Context Clopidogrel therapy improves cardiovascular outcomes in patients with acute
coronary syndromes and following percutaneous coronary intervention by inhibiting …

Background—Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist. This is
the first study to compare the onset and offset of platelet inhibition (IPA) with ticagrelor using …

Context High on-treatment platelet reactivity is associated with atherothrombotic events
following coronary stent implantation. Objective To evaluate the capability of multiple platelet …

Background—The antiplatelet effects of the Platelet Inhibition and Patient Outcomes
(PLATO) trial dose of ticagrelor in patients nonresponsive to clopidogrel and after they …

Background—In the Gauging Responsiveness With A VerifyNow P2Y12 Assay: Impact on
Thrombosis and Safety (GRAVITAS) trial, 6 months of high-dose clopidogrel did not reduce …

Context High residual platelet reactivity (HRPR) in patients receiving clopidogrel has been
associated with high risk of ischemic events after percutaneous coronary intervention (PCI) …

Background: Thienopyridines are metabolized to active metabolites that irreversibly inhibit
the platelet P2Y 12 adenosine diphosphate receptor. The pharmacodynamic response to …